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Abstract 
 
It is generally agreed that the goal of resuscitation is survival with neurological and physiological 
status similar to that preceding the cardiac arrest.   Previously I have argued that the lack of 
improvement in outcome from resuscitation over the past 3 to 4 decades, as compared to the 
substantial progress made in treatment of ischemic heart disease, is a consequence of the absence of 
randomized clinical trials of new interventions and the use of intermediate endpoints such as return of 
spontaneous circulation or admittance to hospital.    Proponents of these intermediate endpoints have 
argued that those involved in the resuscitation have no control over what care is undertaken in the 
hospital and hence hospital mortality only adds noise, at best, thus making survival a less sensitive and 
less relevant endpoint for evaluation of resuscitation interventions.     Recent reports of improvement 
in hospital survival have caused me to consider that their argument may have more validity than I had 
supposed.   In this note I propose a test that gives weight both to the intermediate endpoint and 
survival.   The test is responsive to the primary goal of testing survival with limited loss of power 
compared to a test based only on the intermediate endpoint. The test is illustrated with several 
examples. 
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Introduction 
 
It is generally agreed that the goal of resuscitation is survival with neurological and physiological 
status similar to that preceding the cardiac arrest [2008 AHA endpoint conference]   Previously I have 
argued that the lack of improvement in outcome from resuscitation over the past 3 to 4 decades, as 
compared to the substantial progress made in treatment of ischemic heart disease, is a consequence of 
the absence of randomized clinical trials of new interventions and the use of intermediate endpoints 
such as return of spontaneous circulation (ROSC) or admittance to hospital.    Proponents of these 
intermediate endpoints have argued that those involved in the resuscitation have no control over what 
care is undertaken in the hospital and hence hospital mortality only adds noise making survival a less 
sensitive and less relevant endpoint for evaluation of resuscitation interventions.    Recent reports of 
improvement in hospital survival post resuscitation have caused me to consider that their argument 
may have more validity than I had supposed. [1, 2]   Proponents also point out (figure 1) that sample 
sizes can be substantially smaller with the use of intermediate endpoints. The justification for using 
such intermediate outcomes as the primary endpoint is the belief that they represent a reasonable 
surrogate for survival.  That is, believe that conditional upon achieving the intermediate endpoint, 
subsequent survival should not depend upon an ongoing effect from the interventions administered 
prior to achieving the intermediate endpoint.[3]   A second reason for use of an endpoint such as 
ROSC is logistic; such information can be obtained directly from the agency involved in the 
resuscitation whereas survival requires follow-up with community hospitals which adds cost and 
complexity for its acquisition.    However it should be noted that, in this context, the survival outcome 
does not require lengthy follow-up, a common argument for considering an intermediate endpoint.    
Previously I proposed using the bivariate outcome (intermediate, ultimate) e.g. (hospital admittance, 
survival) and applying a multivariate test such as Hotelling’s T2.[4]    Under the assumption of 
surrogacy such an approach also reduces required sample sizes substantially.   However, the test is 
likely to be significant if there is a large intermediate effect but no net effect and thus this approach 
suffers from many of the issues that relate to surrogate endpoints. 
  
The perils of surrogate endpoints are well recognized.[5, 6]  Indeed, it can be argued that to establish 
an intermediate endpoint as a surrogate for a specific condition and a specific intervention would 
require a trial of such size as to make the use of the intermediate unnecessary.[7]   Instead, believe in 
an intermediate endpoint as a surrogate develops over time as it is found to fit the criteria over a 
number of interventions and through basic research that identifies causal pathways.[8-11]   In a trial 
(TeleCPR) of bystander administered cardio-pulmonary resuscitation (CPR) comparing chest 
compression only versus ventilation and chest compression based on instructions administered over 
the telephone by EMS dispatchers, admittance to the hospital appeared to be a reasonable surrogate for 
survival.[12]    However, at least two trials of interventions in resuscitation question the validity of 
hospital admittance as a surrogate for survival (ARREST, a trial of amiodarone (an antiarrhythmia 
drug) administered at the scene, which found increased hospital admittance but no effect on survival; 
and ASPIRE, a trial of mechanical CPR, which found no effect on hospital admittance but decreased 
survival).[13, 14]   Absence of surrogacy could be that survival, conditional on reaching the positive 
intermediate outcome, was either reduced or increased for the intervention compared to control.   I will 
refer to these as sub- (reverse- if all apparent gain from the intermediate is lost) and super-surrogate 
conditions, as compared with surrogacy in which the effect of the intervention is directionally similar 
and proportionately comparable between the intermediate endpoint and final outcome. 
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A desirable test would reject the intervention if survival was reduced, would optimally weight both the 
intermediate and survival if there was evidence of super-surrogacy, would rely on the intermediate if 
there was no evidence against surrogacy, and would give relatively more weight to survival if there 
was evidence of sub or reverse-surrogacy.   In this note I propose such a test, investigate its properties 
through simulation, and discuss what such a test might have meant for the TeleCPR, ARREST and 
ASPIRE trials and for a potential trial of mild hypothermia (mild hypothermia initiated at the scene of 
the arrest is an intervention that might be supposed to be a super-surrogate in that cooling might help 
achieve ROSC (if given prior to it) and might improve survival conditional on ROSC through its 
impact on the brain and other vital organs. [2, 15])   
 
The Proposed Test W 
 
Notation 
 
Let I represent the intermediate endpoint and S the ultimate endpoint of survival.  Let intervention, T, 
and control, C, represent the therapies to be compared.  Suppose 2N patients are to be randomized, N 
to treatment and N to control.    Let PC   and ∆+= CT PP be the anticipated rates for I under control C 
and treatment T.     Similar let QC  and δ+= CT QQ be the anticipated conditional survival, S|I, rates.   
Let  CTCT qqpp ,,, be the corresponding values for the observed data.   Let ( )ISiS ZZZZ |,,  be the 
normal approximations for the tests comparing proportions.    
 
When Survival is Reduced ( 0<SZ ) 
 
If 0<SZ  (i.e. evidence of harm) set W to SZ  or arbitrarily low, say 0=W .   
 
When there is Potential Super-surrogacy ( 0≥SZ  and 0| >ISZ ) 
 
 If 0≥SZ  (i.e. no evidence of worsened survival) and 0| >ISZ  (i.e. potential of super-surrogacy) set 
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= .     This is an approximately optimal test of the combined outcomes 
(appendix 1). 
  
When there is Evidence of Sub or Reverse Surrogacy ( 0≥SZ  and 0| << LIS CZ ) 
 
If 0≥SZ  and  RSLIS ECZ ˆ6.0| =<  where LC  is negative (evidence of sub or reverse-surrogacy) define 
ISI ZZW |3+= which gives 3 times as much weight to survival as to the intermediate.    Here 
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=∆−==  is the expected value of ISZ |  under TC PQ /∆−=δ  which 
corresponds to the null for S (i.e. reverse-surrogacy).   The choice of the factor 0.6 and the relative 
weight of 3 was based on simulations with the object of protecting against accepting the intervention 
when survival was actually worsened while maintaining the power of the intermediate outcome. 
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 When there is no Evidence of Ultimate Harm and little or no Evidence against Surrogacy 
( 0≥SZ and LIS CZ ≥≥ |0 ) 
 
If 0≥SZ and LIS CZ ≥≥ |0  define IZW =  thus taking advantage of the greater power of the 
intermediate endpoint when surrogacy is likely. 
     
Properties of W 
 
Under the compound null and across a wide range of control rates, 9.01.0 ≤≤ CP  and 9.01.0 ≤≤ CQ , the 
95%tile of W  is given by (appendix 2), 
    CC PQW 05067.009672.0956.195. −+=  
and the 97.5%tile is given by  
    CC PQW 037.007608.0273.2975. −+=   
Indeed for .8 < x < .98, to a very good approximation     
CCx QPW *x)*.7791-(.8346)*x)*.3949-(-(.4245*2)*x*(-2.676x*5.2(-2.213)qnorm(x) +++++= .     
 
The power (appendix 3) of W , IZ and SZ  for a 1 sided .05 level test is displayed in Table 1 for some 
typical intermediate and conditional control outcome rates:  (PC ,QC)= (0.3,0.48), (0.4,0.36) and  
(0.6,0.24), all yielding the same control survival rate of 0.144, under alternatives for the intermediate 
of  PT  = PC and 1.4PC  (respectively null and substantially better intermediate outcome under treatment 
T than control C); and alternatives for the conditional outcome of QT  = 1.2 QC , QC , PC QC / PT , and 
0.8 PC QC / PT (respectively super-surrogacy, surrogacy, reverse-surrogacy, and moderately worsened 
survival).    The sample sizes were choosen to correspond to a power of 0.9 forW  under the 
substantially better intermediate outcome (PT  = 1.4PC)  and surrogacy (QT  = QC). 
 
 
When the null holds for the intermediate outcome, W and SZ  perform similarly (rows 1, 2, and 3).   
When there is a substantial effect on the intermediate outcome, there are clear differences between the 
tests.   Consider the values in italics which correspond roughly to current control rates for ROSC and 
survival conditional on ROSC.    Under super-surrogacy, W and IZ  have the same power, .97, 10% 
higher than SZ .   Under surrogacy IZ has a power of .97 compared to .90 forW and .53 for SZ .   Under 
the null for survival W  has a power of .38.   Under worsened survival W  will exceed the critical value 
10% of the time.    The corresponding N’s required to have a power of .9 for IZ and SZ  are 170 and 
725 respectively. 
 
Results are similar across a wide range of control rates.   For  
      6.03.0 ≤≤ CP , 6.02.0 ≤≤ CQ , and 2/)1( CTC PPP +≤≤ ,  
sample sizes for 80% and 90% power forW , assuming surrogacy, are approximated by 
      )))1log(2421.)log(179.)log(994.1(7799exp(.8. CCCT QQPPN −++−−≈  
 and  
      )))1log(6551.)log(179.1)log(94.1()log(2159.7042exp(.9. CCCTT QQPPPN −++−−+≈ . 
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Dependence of the intermediate outcome and survival conditional on the intermediate outcome 
 
The above results assumed independence of the intermediate outcome and survival conditional on the 
intermediate outcome.   Since the dependency structure will generally be unknown, the critical values 
for W must be determined under an independence model.    However even a strong dependence 
(obtained by requiring a given case to have probabilities for each outcome with the same %tile in the 
respective distributions, i.e. those more likely to achieve the intermediate outcome are more likely to 
survive if the intermediate outcome is achieved and conversely those less likely to achieve the 
intermediate outcome are less likely to survive even if the intermediate outcome is achieved) had 
negligible impact on the test size (i.e. on the alpha level of the test).   Indeed under this strong but 
reasonable dependence, the size of W is negligibly smaller than that of SZ  (based on 4000 simulations 
with N = 1000 and over 9.01.0 ≤≤ CP  and 9.01.0 ≤≤ CQ -appendix 4). 
 
Discussion 
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W attempts to capture the added efficiency when there is evidence for super-surrogacy, the usual 
efficiency of the intermediate outcome when there is evidence for surrogacy and attempts to avoid 
type I error when survival is actually worsened by giving substantial weight to the conditional survival 
comparison when there is evidence of substantial sub-surrogacy.    Even the extreme (though 
directionally likely) violation of the assumption of independence of the intermediate and conditional 
survival outcomes has little effect on the size of W.    W maintains power under super-surrogacy, has 
modest losses in power under surrogacy, and substantial protection against claiming an advantage 
when survival is worse.   There were only modest effects on W when the constant 3 was varied 
between 2.5 and 3.5.   Varying the constant 0.6 in the value for CL essentially traded power under 
surrogacy for protection against surrogacy failure.      
 
Note that W is essentially a one-sided test, which is appropriate for trials comparing a new therapy to a 
standard of care. 
 
The TeleCPR  Study 
 
The TeleCPR study evaluated the effect on survival of bystander CPR administered according to 
instructions from the EMS dispatcher.[12]   The randomly assigned instructions either included steps 
for ventilation and chest compression (ABC-CPR), the standard of care, or steps for chest compression 
only (CC-CPR).   The trial was designed as 1-sided, testing whether  CC-CPR was superior to ABC-
CPR as a previous 1-sided trial had demonstrated that CC-CPR was not inferior to ABC-CPR.    The 
trial terminated with slightly over 500 of a planned 700 patients enrolled when funding ran out.   The 
data is shown in table 2a.   Although there is a slightly greater survival rate conditional on admittance 
to the hospital for the CC-CPR arm (36.1% versus 30.5%), this was not significant (one-sided p = 
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0.25) so surrogacy could not be rejected.   The one-sided p-values for  T2, W , IZ  and SZ  are 0.12, 
0.088, 0.084, and 0.097 respectively.   One of the problems with the bivariate outcome is defining a 
good and a bad outcome.   However, in[4] we show, based on economic considerations, that 
essentially half of the alpha will result in declaring a good outcome under the null.    Because of the 
slight super-surrogacy, W is almost as powerful as IZ  and SZ  loses relatively little power. 
 
The ASPIRE Study 
 
The ASPIRE study was intended to compare manual CPR (the standard of care) with mechanical CPR 
provided by a load distributing band device (the AutoPulse).[13]    To avoid the idiosyncrasies of 
criteria for hospital admission in difference cities, the study considered the endpoint of alive a 4 hours 
post the time of call reporting an out-of-hospital cardiac arrest.    Investigators estimated that control 
rates for this outcome would be 0.178 and anticipated a 35% relative improvement to 0.24 under the 
intervention.    The estimated rate of survival conditional on being alive at 4 hours was about .4.   It 
was unclear whether any additional increment should be expected for survival conditional on being 
alive at 4 hours in the intervention arm.    The sponsor (a startup company funded by venture capital) 
and the investigators wanted to do a survival trial, although it was felt that a neutral impact on survival 
would be a positive result as the device might substantially reduce manpower requirements.    Ignoring 
issues such as sequential monitoring, the sample size required (2alpha = 0.05, power = 0.9) for the 
intermediate endpoint was 2N ~ 1804 and for survival, assuming surrogacy, was 2N ~ 5320.     It was 
consider impossible to raise enough money to do a survival study.   The sample size that would have 
been required for W  and T2 would have been 2N ~ 2224 and 2150 respectively.     The study was 
terminated early due to concerns about safety.    The data is shown in Table 2b.   The slight trend 
toward an improvement in 4 hour survival was not significant.   The one-sided p-values for  T2, IZ  
and SZ  are 0.01, 0.32,  and 0.024 [note the reduction in survival (the secondary endpoint) was 
significant at p = 0.03 after adjustment for baseline covariates].    The point estimates for the 
significant bivariate and survival outcomes are indicative of harm.  The results of the study are being 
largely ignored by the manufacturer on several grounds including that survival was not the primary 
endpoint and the difference was not significant (p = 0.06 when considered as a two-sided test) .    
Whether or not the sponsor could/would have raised the capitol to finance the study if the outcome 
was tested with W is unclear.   The study would undoubtedly have been terminated in the same time 
frame and the value of W would have been 0 as SZ  < 0.     
 
 
The ARREST Study 
 
The ARREST study evaluated the use of amiodarone in patients with out-of-hospital cardiac arrest 
who had not been resuscitated after 3 or more precordial shocks.[14]      This single center study used 
hospital admittance as the primary outcome measure with survival as a secondary outcome.    This 
choice was again made on the practical grounds of financing and feasibility of conducting the study.    
Assuming a control rate for hospital admission of 0.41 and a 30% relative improvement with use of 
amiodarone, and assuming a survival rate conditional on admittance of approximately .38 and 
surrogacy, the sample sizes needed for a 2alpha = 0.05 and power = 0.8 design using T2, W , IZ and 
SZ  would be 2N = 630, 680, 500, and 2090 respectively.     The data are shown in Table 2c.   The 
improvement in admittance rates was significant (one-sided p = 0.019).   Survival was not worse (one-
Hosted by The Berkeley Electronic Press
sided p = 0.52).    It is likely the site might have elected to set the sample size at 680 if they were 
convinced that the test W were a valid means of investigating survival.     The site chose not to 
implement amiodarone as part of standard protocol even though the trial, as designed, had a 
significantly positive outcome.    However, many other EMS systems did include amiodarone in their 
resuscitation protocols.    For the data collected, CL = -1.027, ZS|I = -1.133, W.975 =  2.284, and W = -
1.234.    In this case W would have provided protection against a positive result for an intermediate 
endpoint where there was evidence of reverse-surrogacy.   The one-sided p-value for T2 was 0.025, 
providing an example of how the bivariate outcome can suffer the same problems as the intermediate. 
 
 
A proposed trial of Mild Hypothermia 
 
A novel means of cooling through the nose has been demonstrated, in animal studies, to produce a 
large increase in ROSC long before any real cooling of the brain or vital organs could occur, [16]  but 
also provides rapid core body cooling suggesting the possibility of additional improvement in hospital 
survival as demonstrated in several trials. [2, 15]    The control rates based on current outcomes at a 
number of sites planning to participate in a randomized trial of this novel approach and anticipated 
relative improvements are shown in table 3. 
  
    
Simulation results for IZ , SZ , and W  are shown in Table 4 based on sample sizes which yield a power 
for IZ , SZ  and W  of 0.9 for a 1 sided 0.05 level.    If the trial were sized forW and the super-surrogacy 
assumption holds W  would preserve most of the power of the intermediate, but would relinquish 
about 7 % power compared to the intermediate.  However, under a modest negative effect on survival 
W would indicate a significant positive effect 26% of the time.   At first glance this appears to be 
unacceptable, but is surely better than using IZ  which would have indicated a positive effect 98% of 
the time    Also recall that for W  to be significantly positive SZ  has to be positive and thus the data 
from the trial would not indicate any worsening of survival.  This is similar to the ARREST situation, 
except that the effect of mild hypothermia on the intermediate outcome would have been much greater 
and would probably result in adoption of the therapy by many EMS agencies.    Had the trial been 
sized for SZ  (2N = 1900) but tested with W  this undesirable result would have occurred 14% of the 
time, while the power under surrogacy would be almost 100%.   Under the surrogacy assumption, the 
sample size for the bivariate outcome would be 2N = 526. 
 
 
Would the use of W change the current assessment of the outcomes of clinical trials in EMS? 
 
Ignoring regulatory/approval concerns, the EMS community, being a group of clinician/scientists,  
would consider all evidence including both the intermediate and the survival outcomes when 
evaluating the results of a trial, whether the trial was sized for and tested with T2, IZ , SZ  or W .    
What might the collective judgment be in the case of concern where the unknown truth is that the 
intervention has a large positive effect on the intermediate outcome but a modest negative effect on 
survival and W  yielded a significant p-value?    Figure 2 shows the distribution of IZ and SZ  for such a 
situation (defined by the 4th row of Table 4).    In all cases a large effect on the intermediate and a 
trend (often substantial) toward a positive effect on survival would be seen.    I suspect the EMS 
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community would be inclined to adopt the intervention whether the trial was based on SZ  orW .    If 
based on SZ  adoption would usually be without the “stamp of approval, i.e., p < 0.05”. 
 
There are ethical and practical arguments for and against using W in a clinical trial.    Some would 
argue that only survival matters and only ZS should be used.   Others would argue that if there is no net 
effect on survival then improvement in the ROSC rate is good because more patients may survive with 
improving hospital care.    Still others would argue that if there is no net effect on survival then 
improvement in the ROSC rate is bad because it results in consumption of unnecessary and expensive 
health resources.  Others would argue that too large of sample sizes would have a negative effect on 
efforts to find and test potentially beneficial interventions.  Even if therapies are developed and 
suggest potential in phase II trials using an intermediate endpoint, survival trials would probably have 
to be funded by NIH.    Current funding for the Resuscitation Outcomes Consortium 
(http://www.nih.gov/news/pr/mar2006/nhlbiv1-24.htm) constitutes only a small fraction of what 
would be needed to conduct all the needed trials.   Although each scenario would need to be evaluated, 
in my opinion the proposed test, W, is a compromise that may provide for robust and cost-effective 
evaluation. 
 
References 
 
1. Sunde, K., et al., Implementation of a standardized treatment protocol for post resuscitation 
care after out-of-hospital cardiac arrest. Resuscitation, 2007. 73(1): p. 29-39. 
2. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl 
J Med, 2002. 346(8): p. 549-56. 
3. Prentice, R.L., Surrogate endpoints in clinical trials: definition and operational criteria. Stat 
Med, 1989. 8(4): p. 431-40. 
4. Hallstrom, A.P., What is the appropriate outcome for studies of treatments for out-of-hospital 
cardiac arrest? Resuscitation, 2006. 71(2): p. 194-203. 
5. Fleming, T.R. and D.L. DeMets, Surrogate end points in clinical trials: are we being misled? 
Ann Intern Med, 1996. 125(7): p. 605-13. 
6. Fleming, T.R., Surrogate endpoints and FDA's accelerated approval process. Health Aff 
(Millwood), 2005. 24(1): p. 67-78. 
7. Prentice, R.L., Surrogate and mediating endpoints: current status and future directions. J Natl 
Cancer Inst, 2009. 101(4): p. 216-7. 
8. Yothers, G., Toward progression-free survival as a primary end point in advanced colorectal 
cancer. J Clin Oncol, 2007. 25(33): p. 5153-4. 
9. Daniels, M.J. and M.D. Hughes, Meta-analysis for the evaluation of potential surrogate 
markers. Stat Med, 1997. 16(17): p. 1965-82. 
10. Lipicky, R.J. and M. Packer, Role of surrogate end points in the evaluation of drugs for heart 
failure. J Am Coll Cardiol, 1993. 22(4 Suppl A): p. 179A-184A. 
11. Petrylak, D.P., et al., Evaluation of prostate-specific antigen declines for surrogacy in patients 
treated on SWOG 99-16. J Natl Cancer Inst, 2006. 98(8): p. 516-21. 
12. Hallstrom, A., et al., Cardiopulmonary resuscitation by chest compression alone or with 
mouth-to-mouth ventilation. N Engl J Med, 2000. 342(21): p. 1546-53. 
13. Hallstrom, A., et al., Manual chest compression vs use of an automated chest compression 
device during resuscitation following out-of-hospital cardiac arrest: a randomized trial. Jama, 
2006. 295(22): p. 2620-8. 
Hosted by The Berkeley Electronic Press
14. Kudenchuk, P.J., et al., Amiodarone for resuscitation after out-of-hospital cardiac arrest due 
to ventricular fibrillation. N Engl J Med, 1999. 341(12): p. 871-8. 
15. Bernard, S.A., et al., Treatment of comatose survivors of out-of-hospital cardiac arrest with 
induced hypothermia.[comment]. New England Journal of Medicine., 2002. 346(8): p. 557-63. 
16. Wolfson MR, M.D., Wu J, Hoffman J, Rozenberg A, Shaffer TH, Barbut D, Intranasal 
Perfluorochemical Spray for Preferential Brain Cooling in Sheep. . Neurocritical Care 2008. 
8(3): p. 437-447. 
 
 
 
http://biostats.bepress.com/uwbiostat/paper352
  
 
 
 
 
 
Table 1 
Power o f IZ , SZ  and W  for a 1 sided .05 level test 
I S|I PC ,QC = 0.3,0.48 
N=348 
PC ,QC = 0.4,0.36 
N=250 
PC ,QC = 0.6,0.24 
N=203 
  ZI ZS W ZI ZS W ZI ZS W 
Super-surrogacy 0.051 0.272 0.281 0.051 0.226 0.197 0.048 0.199 0.157 
Surrogacy (Null for S|I) 0.051 0.051 0.051 0.052 0.052 0.052 0.048 0.050 0.050 
 
Null 
 Worsened survival 0.051 0.003 0.013 0.052 0.005 0.014 0.050 0.006 0.014 
Super-surrogacy 0.955 0.953 0.967 0.973 0.873 0.972 1.000 0.810 0.988 
Surrogacy (Null for S|I) 0.953 0.648 0.901 0.975 0.531 0.900 1.000 0.460 0.900 
Reverse surrogacy (Null survival) 0.954 0.050 0.352 0.974 0.050 0.376 1.000 0.050 0.414 
 
Substantial 
effect 
Worsened survival 0.953 0.003 0.062 0.975 0.005 0.100 1.000 0.006 0.152 
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 Table 2  
Table 2a Results of the TeleCPR Trial 
 N Admitted to Hosp Survived|Admitted Survived 
ABC-CPR 278 95 (34.2%) 29 (30.1%) 29 (10.4%) 
CC-CPR 240 97 (40.4%) 35 (36.1%) 35 (14.6%) 
  
Table 2b Results of the ASPIRE Trial 
 N Alive at 4 hours Survived|Alive4hrs Survived 
Manual CPR 373 92 (24.7%) 37 (40.2%) 37 (9.9%) 
AutoPulse 394 104 (26.4%) 23 (22.1%) 23 (5.8%) 
  
Table 2c Results of the ARREST Trial 
 N Admitted Survived|Admitted Survived 
Control 258 89 (34.5%) 34 (38.2%) 34(13.2%) 
Amiodarone 246 108(43.9%) 33 (30.6%) 33 (13.4%) 
 
http://biostats.bepress.com/uwbiostat/paper352
 Table 3 
Expected control and intervention rates for the intermediate outcome (ROSC) and survival 
conditional on ROSC in a trial of mild hypothermia treatment for Out-of-Hospital Cardiac Arrest. 
 Control 
 Rates 
Expected Rates Under  
Intervention 
Assumed 
Improvement 
    
I (ROSC) 40% 54% 14% 
S|I (Survival conditional on ROSC) 36% 41.4% 5.4% 
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 Table 4 
Power of IZ , SZ  and W  for a 1 sided .05 level test with  PC ,QC = 0.4,0.36 
 
I S|I 2N=422 2N=1900 2N=650 
  ZI ZS W ZI ZS W ZI ZS W 
δ = .054      Super-surrogacy 0.900 0.684 0.873 1.000 0.998 1.000 0.976 0.838 0.966 
δ = 0           Surrogacy (Null for S|I) 0.901 0.397 0.774 1.000 0.902 0.994 0.975 0.529 0.898 
δ = -.0933  Reverse surrogacy (Null for S)  0.902 0.050 0.370 1.000 0.051 0.308 0.977 0.050 0.377 
∆=.14 
Large 
Effect 
on I δ = -.1102  Worsened survival 0.899 0.028 0.281 1.000 0.013 0.141 0.977 0.023 0.258 
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Figure 1 
 
 
Endpoints and Sample Size in the Setting of Out-of-
Hospital Cardiac Arrest
(25% improvement in outcome)
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Discharge alive from hospital neurologically intact    p ~ .05  2N ~ 21888
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Figure 2 
 
Values of ZI  by ZS when there is a large positive effect on the intermediate
outcome, a modest negative effect on survival, and W is significant.
ZI
ZS
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Appendix 1 
 
An approximately optimal statistic when 0≥SZ  (i.e. no evidence of worsened survival) and 0| >ISZ  
(i.e. potential of super-surrogacy). 
 
 Under the null of no treatment effect on I, )1,0(~/)( NppNZ ICTI σ−=  with PPI ~22 =σ  where 
2/)( CT PPP +=  and PP −= 1~ .     Similarly under the null of no treatment effect conditional on I, 
( )1,0~/)( || NqqNZ ISCTIS σ−=  where 
CTCT
IS PP
PQQ
PP
QQ ~211~2| =





+=σ .    Thus under the 
composite null, ( )1,0~),( | NbZaZbaZZ ISI +==  provided 122 =+ ba .  Under the alternatives, 
∆+= CT PP  and δ+= CT QQ , )1,/(~ II NNZ σ∆  where CCTTI PPPP
~~
~ +σ  and 
( )1,/~ || ISIS NNZ σδ  where 
C
CC
T
TT
IS P
QQ
P
QQ ~~
~
2
| +σ  so, if the conditional outcome is independent of 
the intermediate outcome, ( )( )1,//~ | NbaNZ SUS σδσ +∆ .    The null is rejected in favor of the 
alternative if 2/1 α−> ZZ so the power is ( )( )2/1|//)( αβ σδσ −−+∆Φ=−Φ ZNbaZ ISI .  This is 
maximized when 0| >ISZ  with the ratio
IS
I
b
a
|/
/
σδ
σ∆
= .   Estimating from the data, 
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I
Z
Z
N
N
b
a
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=
∆
=
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σ
 and substituting would give an approximately optimal 
statistic
2
|
2
2
|
2
|
ISI
ISI
ISI
ZZ
ZZ
bZaZZ
+
+
≈+= .    Thus if 0≥SZ  (i.e. no evidence of worsened survival) and 
0| >ISZ  (i.e. potential of super-surrogacy) an approximately optimal statistic is given by  
2
|
2
2
|
2)(
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ISII
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ZZZsign
W
+
+
= .   
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Appendix 2 
 
S-plus program for the value for W, WC, corresponding to the Cth %tile across 
A wide range of intermediate (.1-.9) and conditional (.1-.9) outcome rates 
 
nsim_100000 
N_1000 
C_.95 
wc_vector(length=0) 
for (Pc in .1*(1:9)){ 
Pc_Pc 
for (Qc in .1*(1:9)){ 
Qt_Qc 
x1_rbinom(nsim,N,Pc) 
x2_rbinom(nsim,N,Pc) 
mx2_x2/N 
mx1_x1/N 
rx_(x1+x2)/(2*N) 
sigx_(rx*(1-rx)/N)**.5 
y1_rbinom(nsim,x1,Qc) 
y2_rbinom(nsim,x2,Qt) 
my2_y2/x2 
my1_y1/x1 
ry_(y1+y2)/(x1+x2) 
sigy_(ry*(1-ry)*2/(x1+x2))**.5 
u_y1-y2 
x_((x1/N)-(x2/N))/(2**.5*sigx) 
y_((y1/x1)-(y2/x2))/(2**.5*sigy) 
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null 
#survival effect 
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5 
CL_.6*EZrs 
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+ 
(y<CL)*(x+3*y))+(u<0)*0#computes W 
hist(w,nclass=200) 
wo_w[order(w)] 
wc_rbind(wc,c(Pc,Qc,wo[C*nsim])) 
}} 
wcregression_lm(wc[,3]~wc[,1]+wc[,2]) 
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 Appendix 3 
  
S-plus program for comparing power of Zi, Zs, and W for specific control rates and 
alternatives for the intermediate of null and substantial improvement and alternatives for 
the conditional survival corresponding to super-surrogacy, surrogacy, reverse-surrogacy and 
worsened survival 
 
nsim_100000 
N_250 #number per group 
Pc_.4 #Control rate for intermediate outcome 
Qc_.36 #Control rate for conditional survival 
power_vector(length=0) 
for (Pt in c(Pc,1.4*Pc)){#null and substantial improvement for intermediate outcome 
for (Qt in c(Qc*1.2,Qc,Pc*Qc/Pt,.8*Pc*Qc/Pt)){#super-surrogacy, surrogacy, reverse-
surrogacy, #worsened survival 
x1_rbinom(nsim,N,Pt) 
x2_rbinom(nsim,N,Pc) 
mx2_x2/N 
mx1_x1/N 
rx_(x1+x2)/(2*N) 
sigx_(rx*(1-rx)/N)**.5 
y1_rbinom(nsim,x1,Qt) 
y2_rbinom(nsim,x2,Qc) 
my2_y2/x2 
my1_y1/x1 
ry_(y1+y2)/(x1+x2) 
sigy_(ry*(1-ry)*2/(x1+x2))**.5 
ru_(y1+y2)/(2*N) 
u_((y1-y2)/N)/(ru*(1-ru)*2/N)**.5 
x_((x1/N)-(x2/N))/(2**.5*sigx) 
y_((y1/x1)-(y2/x2))/(2**.5*sigy) 
w95_1.956 + (-0.05067*Pc) +  (.09672*Qc)#critical value for W-see appendix 1 
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null 
#survival effect 
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5 
CL_.6*EZrs 
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+ 
(y<CL)*(x+3*y))+(u<0)*0#computes W 
pw_sum(w>=w95)/nsim 
px_sum(x>=1.64)/nsim 
pu_sum(u>=1.64)/nsim 
power_rbind(power,c(px,pu,pw)) 
}}
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 Appendix 4  
 
S-plus program for creating dependent outcome data and evaluating size 
 
#converting mean, m, and stdev, s, into alpha and beta parameter 
#for beta dist (NOTE s**2<m-m**2)!!!!!!! 
betapara_function(m,s) 
 {if (s**2>=m-m**2) return("warning") 
  if(s**2<m-m**2) 
 {b_(((m/s)**2)*(1-m)**2/m)-(1-m) 
 a_(m/(1-m))*b 
 return(c(a,b))}} 
  
getdata_function(nsims,Pc,Pt,Qc,Qt,N){ 
#for control 
pab_betapara(Pc,.05)#returns the parameters of a beta dist with mean Pc and stdev .05 
pc_rbeta(nsims*N,pab[1],pab[2])#generates individual probabilities for intermediate outcome 
qab_betapara(Qc,.05) 
qc_qbeta(pbeta(pc,pab[1],pab[2]),qab[1],qab[2])#generates individual probabilities for 
#survival conditional on intermediate outcome with same %tile as the individuals %tile 
#for probability of the intermediate outcome 
xc_rbinom(nsims*N,1,pc)#generates the intermediate outcome 
qc_qc*xc#sets the conditional survival probability to zero if the intermediate outcome is 
not #reached 
yc_rbinom(nsims*N,1,qc)#generates the survival outcome 
#for intervention 
pab_betapara(Pt,.05) 
pt_rbeta(nsims*N,pab[1],pab[2]) 
qab_betapara(Qt,.05) 
qt_qbeta(pbeta(pt,pab[1],pab[2]),qab[1],qab[2]) 
xt_rbinom(nsims*N,1,pt) 
qt_qt*xt 
yt_rbinom(nsims*N,1,qt) 
return(rbind(xc,yc,xt,yt))} 
 
#driver 
nsim_100 
N_1000 
k_40#total number of simulations is k*nsim 
out_vector(length=0) 
for (i in 1:k){ 
power_vector(length=0) 
for (Pc in .1*(1:9)){ 
for (Qc in .1*(1:9)){ 
data_getdata(nsim,Pc,Pc,Qc,Qc,N) 
xc_data[1,] 
xt_data[3,] 
yc_data[2,] 
yt_data[4,] 
xc_matrix(xc,N,nsim) 
xt_matrix(xt,N,nsim) 
yc_matrix(yc,N,nsim) 
yt_matrix(yt,N,nsim) 
x1_colSums(xc) 
x2_colSums(xt) 
y1_colSums(yc) 
y2_colSums(yt) 
mx2_x2/N 
mx1_x1/N 
rx_(x1+x2)/(2*N) 
sigx_(rx*(1-rx)/N)**.5 
my2_y2/x2 
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my1_y1/x1 
ry_(y1+y2)/(x1+x2) 
sigy_(ry*(1-ry)*2/(x1+x2))**.5 
ru_(y1+y2)/(2*N) 
u_((y1-y2)/N)/(ru*(1-ru)*2/N)**.5#computes Zs 
x_((x1/N)-(x2/N))/(2**.5*sigx)#computes Zi 
y_((y1/x1)-(y2/x2))/(2**.5*sigy)#computes Zs|i 
w95_1.956 + (-0.05067*Pc) +  (.09672*Qc)#critical value for W-see appendix 1 
delnull_mx2*my2/(mx1)-my2#estimates the conditional survival delta corresponding to null 
#survival effect 
EZrs_delnull*(((mx1+mx2)/2)*N)**.5/(((my1+my2)/2)*(1-((my1+my2)/2)))**.5 
CL_.6*EZrs 
w_(u>=0)*((y>=0)*(sign(x)*x**2+y**2)/((x**2+y**2+.00001)**.5)+(y<0)*(y>=CL)*x+ 
(y<CL)*(x+3*y))+(u<0)*0#computes W 
pw_sum(w>=w95)/nsim 
px_sum(x>=1.64)/nsim 
pu_sum(u>=1.64)/nsim 
power_rbind(power,c(Pc,Qc,px,pu,pw)) 
}} 
out_cbind(out,power)} 
#averages across the k runs and reassembles matrix 
pq_out[,1:2] 
pw_out[,5*(1:k)-0] 
pu_out[,5*(1:k)-1] 
px_out[,5*(1:k)-2] 
pwa_rowMeans(pw) 
pua_rowMeans(pu) 
pxa_rowMeans(px) 
size_cbind(pq,pxa,pua,pwa) 
wusize_lm(size[,5]-size[,4]~size[,1]+size[,2]) 
wusize 
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